




The relative strengths and weaknesses of GT Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 13% points. The greatest weakness of GT Biopharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 161% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	8,106
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,319
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-15,932
Other Revenues	0
Property and Equipment	0
Research and Development	3,472
Selling, General and Administrative Expense	8,950

Output Variable	Value in 1000 USD
Assets	8,106
Liabilities	2,319
Expenses	12,422
Revenues	0
Stockholders Equity	5,787
Net Income	-28,354
Comprehensive Net Income	-28,354
BaseVar	19,390
ECR before LimitedLiability	-302%
Economic Capital Ratio	68%